Form 4: Roivant Director's Equity Grant & Tax Settlement

Roivant Sciences Director James C. Momtazee reported an acquisition of 609 common shares as a compensation award and a disposition of 122 shares for tax withholding, resulting in a net beneficial ownership of 109,030 shares.

Summary

• James C. Momtazee, a Director of Roivant Sciences Ltd. (ROIV), reported transactions involving the company's common shares.
• Acquired 609 common shares on January 20, 2026, as an award under the Issuer's Non-Employee Director Compensation Plan, fully vested as of the grant date.
• Disposed of 122 common shares on January 20, 2026, at a price of $22.98 per share.
• The disposition represents a 'net settlement' by Roivant Sciences to satisfy applicable tax withholding obligations related to the vesting and settlement of the common shares.
• Following these transactions, beneficial ownership stands at 109,030 common shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine director compensation and tax-related dispositions, indicating ongoing director involvement and standard corporate practices, without suggesting any significant positive or negative operational or financial developments for the company.

Positives

• Director James C. Momtazee received an equity award of 609 common shares, indicating continued compensation and alignment of interests with shareholders.
• The award was fully vested as of the grant date, providing immediate ownership.

Negatives

• A portion of the awarded shares (122 shares) was disposed of to cover tax withholding obligations, which is a standard practice but reduces the net shares retained by the director.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The reported transactions are routine for publicly traded companies, reflecting standard non-employee director compensation practices and the associated tax settlements. Such equity grants are a common method to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• The practice of granting equity as compensation to non-employee directors is a widely accepted corporate governance standard across industries, including the biotechnology and pharmaceutical sectors where Roivant Sciences operates.
• The 'net settlement' method for satisfying tax withholding obligations upon the vesting of equity awards is also a common and efficient practice, comparable to how many companies like Pfizer, Merck, or Johnson & Johnson manage executive and director equity compensation.

Corporate Governance

Related Party Transactions

• The acquisition of common shares by Director James C. Momtazee under the Non-Employee Director Compensation Plan constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Minor, routine dilution from the issuance of new shares for compensation, partially offset by the tax settlement. Overall, it reflects standard governance and compensation practices.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 details routine director compensation and a subsequent tax-related share disposition. Such transactions are standard and do not typically indicate a change in the company's fundamental outlook or warrant a significant shift in investment strategy. The information provided is insufficient to alter a 'hold' recommendation based solely on these routine insider activities.

Keywords

Roivant Sciences, ROIV, Form 4, Insider Transaction, Director Compensation, Equity Award, Stock Grant, Tax Withholding, Rule 10b5-1